Last $0.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
CAPS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Open
$0.20
Previous Close
$0.20
Day High
$0.20
Day Low
$0.20
52 Week High
09/11/14 - $0.39
52 Week Low
11/14/14 - $0.19
Market Cap
8.1M
Average Volume 10 Days
12.5K
EPS TTM
$-0.10
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPSTONE THERAPEUTICS CORP (CAPS)

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing a pipeline of peptides and other molecules for helping patients with under-served medical conditions. It develops AZX100, a novel synthetic 24-amino acid peptide that has completed Phase 2 study for dermal scarring, and is in pre-clinical studies for Pulmonary Fibrosis and Peridural Fibrosis; and Apo E mimetic peptide molecule AEM-28 and its analogs that play an important role in lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 11/13/14
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $120.0K
Consultant
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 01:45 PM

Capstone Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 01:45 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Capstone Therapeutics and LipimetiX Development Announce Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals

Capstone Therapeutics and its joint venture affiliate, LipimetiX Development, LLC announced the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed a generally acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints, which included: p < 0.05 favoring AEM-28 vs. placebo within the first 12 hours post infusion at the high dose tested of 3.54mg/kg in VLDL, equating to a maximum 76% drop in VLDL vs. baseline and a 56% net maximum reduction of VLDL vs. placebo; p < 0.05 favoring AEM-28 vs. placebo within the first 12 hours post infusion at the 2 mg/kg dose in VLDL, equating to a maximum 70% drop in VLDL vs. baseline and a 41% net maximum reduction of VLDL vs. placebo; p < 0.025 favoring AEM-28 vs. placebo within the first 12 hours post infusion at the high dose tested of 3.54 mg/kg in triglycerides, equating to a maximum 74% drop in triglycerides vs. baseline and a 55% average net maximum reduction of triglycerides vs. placebo; p < 0.025 favoring AEM-28 vs. placebo within the first 12 hours post infusion at the 2 mg/kg dose in triglycerides, equating to a 71% drop in triglycerides vs. baseline and a 45% net maximum reduction of triglycerides vs. placebo. The JV has a development plan, subject to continued favorable study results and funding availability, to pursue regulatory approval of AEM-28 and/or analogs as treatment for Homozygous Familial Hypercholesterolemia (granted Orphan Drug Designation by FDA in 2012), Acute Hypertriglyceridemic Pancreatitis and other Orphan indications in hyperlipidemia. The JV may possibly explore additional indications for its family of Apo E mimetic peptides including Acute Coronary Syndrome, Peripheral Artery Disease and mixed dyslipidemia Type 2 Diabetes.

Capstone Therapeutics Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Capstone Therapeutics Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from continuous operations before taxes of $1,234,000 compared to $1,202,000 a year ago. The company incurred a net loss of $1.2 million compared to a net loss of $1.2 million in the third quarter of 2013. Net loss is affected by the inclusion of the operating expenses of joint venture, LipimetiX Development, LLC, which totaled (net of intercompany transactions) $790,000 for the three months ended September 30, 2014, and $840,000 for the three months ended September 30, 2013. Net loss per basic and diluted share attributable to the company stockholders was $0.03 compared to $0.03 a year ago. For the nine months, the company reported loss from continuous operations before taxes of $3,647,000 compared to $3,420,000 a year ago. The company incurred a net loss of $3.6 million compared to a net loss of $3.2 million in 2013. Net loss in 2014 increased primarily due to less other income in 2014 and the allocation of 100% of the joint venture losses to the company in 2014. Net loss per basic and diluted share attributable to the company stockholders was $0.09 compared to $0.08 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.20 USD 0.00

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies
 

Industry Analysis

CAPS

Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit www.capstonethx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.